QTTB icon

Q32 Bio

1.64 USD
+0.04
2.50%
At close Apr 4, 4:00 PM EDT
After hours
1.55
-0.09
5.49%
1 day
2.50%
5 days
-4.09%
1 month
-24.07%
3 months
-55.19%
6 months
-96.34%
Year to date
-52.46%
1 year
-92.08%
5 years
-98.95%
10 years
-99.02%
 

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Employees: 42

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

120% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 10

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

25% more funds holding

Funds holding: 72 [Q3] → 90 (+18) [Q4]

14.72% more ownership

Funds ownership: 75.56% [Q3] → 90.28% (+14.72%) [Q4]

88% less call options, than puts

Call options by funds: $62K | Put options by funds: $498K

91% less capital invested

Capital invested by funds: $406M [Q3] → $37.8M (-$368M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
83%
upside
Avg. target
$7.33
347%
upside
High target
$15
815%
upside

3 analyst ratings

positive
0%
neutral
100%
negative
0%
Wells Fargo
Derek Archila
39% 1-year accuracy
12 / 31 met price target
815%upside
$15
Equal-Weight
Maintained
12 Mar 2025
BMO Capital
Etzer Darout
15% 1-year accuracy
5 / 33 met price target
83%upside
$3
Market Perform
Downgraded
11 Feb 2025
Piper Sandler
Christopher Raymond
24% 1-year accuracy
7 / 29 met price target
144%upside
$4
Neutral
Downgraded
11 Feb 2025

Financial journalist opinion

Neutral
PRNewsWire
3 weeks ago
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 -- -- Cash and cash equivalents of $78.0 million as of December 31, 2024 expected to provide financial runway into 2H'26 -- WALTHAM, Mass. , March 11, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Neutral
PRNewsWire
4 weeks ago
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for remittive effect; multiple inbound patient requests to re-initiate dosing -- -- In the Phase 2a clinical trial, bempikibart was observed to be safe and well-tolerated, with PK supporting subcutaneous dosing and receptor occupancy data demonstrating desired target engagement; clinical biomarkers showed changes in Th2 biomarkers, and expected on-mechanism changes in T-cells, indicative of potent IL-7 and TSLP inhibition -- -- Bempikibart development program remains on track with open-label extension study to initiate in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- WALTHAM, Mass. , March 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL.
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Neutral
PRNewsWire
1 month ago
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL.
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Neutral
PRNewsWire
1 month ago
Q32 Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Date: Wednesday, March 5, 2025 Presentation Time: 11:50 a.m.
Q32 Bio to Participate in Upcoming March Investor Conferences
Neutral
PRNewsWire
1 month ago
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
-- Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; SIGNAL-AA Part B remains on track for initiation of dosing in 1H'25, with topline data expected in 1H'26 -- -- Company to discontinue renal basket trial for ADX-097 to conserve resources and evaluate strategic options for its tissue-targeted complement inhibitor platform -- -- Cash runway expected to extend to 2H'26 -- WALTHAM, Mass. , Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA).
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Neutral
PRNewsWire
1 month ago
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m.
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Positive
Zacks Investment Research
2 months ago
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?
Negative
Zacks Investment Research
3 months ago
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
Negative
Benzinga
3 months ago
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
On Wednesday, Q32 Bio Inc.  QTTB revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA).
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
Negative
Investors Business Daily
3 months ago
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low. The post Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment appeared first on Investor's Business Daily.
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
Charts implemented using Lightweight Charts™